At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Vemurafenibdrug
Likely dose
Vemurafenib 960 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine
In Brief
A Phase 2 clinical trial evaluating Vemurafenib for Neoplasms. Completed, enrolled 51 participants across 16 sites in 4 countries.
Detailed Summary
This open-label, multi-center study will evaluate the safety and efficacy of Vemurafenib (RO5185426) in participants with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine therapy. Participants will receive vemurafenib 960 milligrams (mg) orally twice daily until progressive disease or unacceptable toxicity occurs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesFrance, Italy, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartJun 2011
Primary CompletionNov 2014
Study CompletionMay 2015
TodayJul 2026
First PostedJan 31, 2011
Enrollment StartJun 1, 2011
Primary CompletionNov 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 15.4 years ago
Interventions
Vemurafenibdrug
Vemurafenib 960 mg orally twice daily.